Ticker Details
uniQure N.V. Ordinary Shares uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
IPO Date:	March 1, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.53B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.67 | 3.00%
Avg Daily Range (30 D):	$0.91 | 4.39%
Avg Daily Range (90 D):	$0.92 | 4.90%

Institutional Daily Volume
Avg Daily Volume:	.7M
Avg Daily Volume (30 D):	1.75M
Avg Daily Volume (90 D):	2.61M

Trade Size
Avg Trade Size (Sh.):	94
Avg Trade Size (Sh.) (30 D):	80
Avg Trade Size (Sh.) (90 D):	91

Institutional Trades
Total Institutional Trades:	3,320
Avg Institutional Trade:	$1.71M
Avg Institutional Trade (30 D):	$2.11M
Avg Institutional Trade (90 D):	$2.07M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.11M
Avg Closing Trade (30 D):	$2.59M
Avg Closing Trade (90 D):	$3.01M
Avg Closing Volume:	102.78K

News

May 21, 2026 @ 2:30 PM Numero AI and Royu Merge to Redefine How Finance T... Source: Not Specified

Apr 13, 2026 @ 1:00 PM QURE Investors Have Opportunity to Lead uniQure N.... Source: The Schall Law Firm

Apr 10, 2026 @ 5:53 PM INVESTOR DEADLINE: uniQure (QURE) Investors with S... Source: Hagens Berman

Apr 8, 2026 @ 8:57 PM INVESTOR DEADLINE: uniQure (QURE) Investors with S... Source: Hagens Berman

Apr 8, 2026 @ 1:47 AM uniQure N.V. Securities Fraud Class Action Result ... Source: Kahn Swick & Foti, Llc

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-3.48	$-.85	$-.56
Diluted EPS	$-3.48	$-.85	$-.56
Revenue	$18.09M	$3.56M	$5.57M
Gross Profit	$16.39M	$3.34M	$5.13M
Net Income / Loss	$-208.87M	$-53.54M	$-37.09M
Operating Income / Loss	$-191.74M	$-45.72M	$-51.12M
Cost of Revenue	$1.71M	$.22M	$.44M
Net Cash Flow	$-77.12M	$59.74M	$-516.75M
PE Ratio